

Subst. Form PTO-1449 APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 26473/04200		Serial No.: Not yet 10/052,589 assigned
	Applicant: Perez, et al.		Group: Not yet assigned 1632
	Filing Date: Concurrently herewith		

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
Amz	AA	5,556,753	September 17, 1996	Bard, et al.			Nov. 4, 1994
Amz	AB	5,861,309	January 19, 1998	Bard, et al.			Aug. 21, 1995
Amz	AC	6,057,349	May 2, 2000	Cournoyer, et al.			Mar. 8, 1999
	AD						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AE						
	AF						
	AG						
	AH						
	AI						

OTHER PRIOR ART

Amz	AJ	"Overexpression of the α_{1B} -adrenergic receptor causes apoptotic neurodegeneration: Multiple system atrophy" by Zuscik, et al., <u>Nature Medicine</u> , Vol. 6, No. 12, December 2000, pp. 1388-1394.
	AK	"Constitutive Activation of a Single Effector Pathway: Evidence for Multiple Activation States of a G-Protein-Coupled Receptor" by Perez, et al., <u>Molecular Pharmacology</u> , Vol. 49, pp. 112-122 (1996).
	AL	"Cloning, Cell-Type Specificity, and Regulatory Function of the Mouse α_{1B} -Adrenergic Receptor Promoter" by Zuscik, et al., <u>Molecular Pharmacology</u> , Vol. 56, pp. 1288-1297 (1999).
	AM	"Genetic Alteration of α_{2C} -Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedetomidine, a Subtype-Nonselective α_2 -Adrenoceptor Agonist" by Sallinen, et al., <u>Molecular Pharmacology</u> , Vol. 51, pp. 36-46 (1997).
	AN	"Synergism of Constitutive Activity in α_1 -Adrenergic Receptor Activation" by Hwa, et al., <u>Biochemistry</u> , Vol. 36, No. 3, pp. 633-639 (1997).
↓	AO	"Endothelin-1 Transgenic Mice Develop glomerulosclerosis, Interstitial Fibrosis and Renal Cysts but not Hypertension" by Hoher, et al., <u>J. Clin. Invest.</u> , Vol. 99, No. 6, pp. 1380-1389 (March 1997).
Amz	AP	"Myocardial Expression of a Constitutively Active α_{1B} -Adrenergic Receptor in Transgenic Mice Induces Cardiac Hypertrophy" by Milano, et al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, pp. 10109-10113 (October 1994).
	AQ	
	AR	

Examiner: Anne-Marie Zalk

Date Considered: 9/29/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

C m p l t i f K n w n

Application Number	10/052,589
---------------------------	-------------------

Filing Date	January 18, 2002
--------------------	-------------------------

First Named Inventor	Dianne M. Perez
-----------------------------	------------------------

Group Art Unit	1632
----------------	------

Examiner Name	Not yet assigned
---------------	------------------

Attorney Docket Number	26473/04200
------------------------	-------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Anne-Marie Falk

Date
Considered

9/29/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Compleat if Kn wn

Application Number	10/052,589
Filing Date	January 18, 2002
First Named Inventor	Dianne M. Perez
Group Art Unit	1632
Examiner Name	Not yet assigned
Attorney Docket Number	26473/04200

TECH CENTER 1500/2900

APR 23 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4.	PEREZ, ET AL., "Constitutive Activation of a Single Effector Pathway: Evidence for Multiple Activation States of a G Protein-Coupled Receptor" Molecular Pharmacology, 49:112-122 (1996).	
	5.	ZUSCIK, ET AL., "Cloning, Cell-Type Specificity, and Regulatory Function of the Mouse •1B-Adrenergic Receptor Promoter" Molecular Pharmacology, 56:1288-1297 (1999).	
	6.	SALLINEN, ET AL., "Genetic Alteration of •2C-Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedetomidine, a Subtype-Nonselective •2-Adrenoceptor Agonist" Molecular Pharmacology, 51:36-46 (1997).	
	7.	HWA, ET AL., "Synergism of Constitutive Activity in •1-Adrenergic Receptor Activation" Biochemistry, Vol. 36, No. 3, pp. 633-639, 1997.	
	8.	HOCHER, ET AL., "Endothelin-1 Transgenic Mice Develop Glomerulosclerosis, Interstitial Fibrosis, and Renal Cysts but not Hypertension" J. Cline. Invest., Vol. 99, No. 6, March 1997, 1380-1389.	
	9.	MILANO, ET AL., "Myocardial expression of a constitutively active •1B-Adrenergic receptor in transgenic mice induces cardiac hypertrophy" Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 10109-10113, October 1994,	
	10.	ZUSCIK, ET AL., "Overexpression of the •1B-adrenergic receptor causes apoptotic neurodegeneration: Multiple system atrophy" Nature Medicine, Vol. 6, No. 12, December 2000, pp. 1388-1394.	

Examiner
Signature

Anne-Marie Falk

Date
Considered

9/29/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Subst. Form PTO-1449	Atty. Docket No.: 26473/04200	Serial No.: 10/052,589
APPLICANT'S INFORMATION DISCLOSURE STATEMENT	RECEIVED AUG 06 2002	
Applicant: Perez, et al.		Group: 1632
Filing Date: January 18, 2002		
TECH CENTER 1600/2900 U.S. PATENT DOCUMENTS		

Initial*	Document No.	Date	Name	Class	Subcl.	Filing Date
AA						
AB						
AC						
AD						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AE						
AF						
AG						
AH						
AI						

OTHER PRIOR ART

Amz	AJ	"Transgenic Mice with Cardiac Overexpression of α_{1B} -Adrenergic Receptors" by Akhter, et al., <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 34, August 22, 1997, pp. 21253-21259.
	AK	"Regions of the α_1 -adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function" by Cotecchia, et al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 87, April 1990, pp. 2896-2900.
	AL	"Nervous System, Anatomy" by Gaudin, A.J., <u>Encyclopedia of Human Biology</u> , 2d Ed., Volume 6, ed. Renato Dulbecco, Academic Press, New York, 1997.
	AM	"Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human β_2m : An Animal Model of HLA-B27-Associated Human Disorders" by Hammer, et al., <u>Cell</u> , Vol. 63, November 30, 1990, pp. 1099-1112.
	AN	"Expression of the DBA/2J <i>Ren-2</i> gene in the adrenal gland of transgenic mice" by Mullins, et al., <u>The EMBO Journal</u> , Vol. 8, No. 13, 1989, pp. 4065-4072.
	AO	"Fulminant hypertension in transgenic rats harbouring the mouse <i>Ren-2</i> gene" by Mullins, et al., <u>Nature</u> , Vol. 344, April 5, 1990, pp. 541-544.
	AP	"Viewpoint: Are Studies in Genetically Altered Mice Out of Control?" by Sigmund, C. D., <u>Arterioscler Thromb Vasc. Biol.</u> 2000;20:1425-1429.
	AQ	"HLA-B27 in Inbred and Non-Inbred Transgenic Mice: Cell Surface Expression and Recognition as an Alloantigen in the Absence of Human β_2 -Microglobulin" by Taurog, et al., <u>The Journal of Immunology</u> , Vol. 141, No. 11, December 1, 1988, pp. 4020-4023.
Amz	AR	"Transgenic Livestock: Progress and Prospectus for the Future" by Wall, R.J., <u>Theriogenology</u> , 45:57-68, 1996.
Examiner:	Anne-Marie Falk	
Date Considered:	9/29/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.